首页> 美国卫生研究院文献>AAPS PharmSciTech >Evaluation of a Nanoemulsion-Based Formulation for Respiratory Delivery of Budesonide by Nebulizers
【2h】

Evaluation of a Nanoemulsion-Based Formulation for Respiratory Delivery of Budesonide by Nebulizers

机译:基于纳米乳剂的雾化器布地奈德呼吸递送的评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this work was to evaluate the in vitro performance of a nebulized nanoemulsion formulation which had been optimised previously. To do so, a transparent nanoemulsion preparation containing 1.5 mg/ml of budesonide was prepared and diluted to achieve concentrations of 250 and 500 μg/ml budesonide. The in vitro characteristics of the diluted nanoemulsions were then compared with the commercially available suspension of budesonide (Pulmicort Respules®) when nebulized using a jet and a vibrating mesh nebulizer. A smaller MMAD with improved aerosol output was observed in the nanoemulsion preparations compared with the corresponding suspension formulations indicating an improved in vitro performance for the nanoemulsion-based preparations.
机译:这项工作的目的是评估先前已优化的雾化纳米乳剂的体外性能。为此,制备了含有1.5 mg / ml布地奈德的透明纳米乳液制剂并稀释至250和500μg/ ml布地奈德的浓度。然后,使用喷嘴和振动筛网雾化器进行雾化时,将稀释的纳米乳剂的体外特性与布地奈德的市售悬浮液(Pulmicort Respules?)进行比较。与相应的悬浮液制剂相比,在纳米乳剂制剂中观察到较小的具有改善的气溶胶输出的MMAD,这表明基于纳米乳剂的制剂具有改善的体外性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号